Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cosmo Pharmaceuticals S.p.A - Product Pipeline Review - 2014', provides an overview of the Cosmo Pharmaceuticals S.p.A's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cosmo Pharmaceuticals S.p.A's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cosmo Pharmaceuticals S.p.A including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cosmo Pharmaceuticals S.p.A's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cosmo Pharmaceuticals S.p.A's pipeline products

Reasons to buy

- Evaluate Cosmo Pharmaceuticals S.p.A's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cosmo Pharmaceuticals S.p.A in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cosmo Pharmaceuticals S.p.A's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cosmo Pharmaceuticals S.p.A and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cosmo Pharmaceuticals S.p.A
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cosmo Pharmaceuticals S.p.A and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cosmo Pharmaceuticals S.p.A Snapshot 5
Cosmo Pharmaceuticals S.p.A Overview 5
Key Information 5
Key Facts 5
Cosmo Pharmaceuticals S.p.A - Research and Development Overview 6
Key Therapeutic Areas 6
Cosmo Pharmaceuticals S.p.A - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cosmo Pharmaceuticals S.p.A - Pipeline Products Glance 14
Cosmo Pharmaceuticals S.p.A - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Cosmo Pharmaceuticals S.p.A - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Cosmo Pharmaceuticals S.p.A - Drug Profiles 17
mesalamine ER 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
rifamycin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
budesonide ER 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CB-0601 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CB-0602 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Low Molecular Weight Heparin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AS-101 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
naloxone hydrochloride 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cosmo Pharmaceuticals S.p.A - Pipeline Analysis 29
Cosmo Pharmaceuticals S.p.A - Pipeline Products by Target 29
Cosmo Pharmaceuticals S.p.A - Pipeline Products by Route of Administration 30
Cosmo Pharmaceuticals S.p.A - Pipeline Products by Molecule Type 31
Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action 32
Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates 34
Cosmo Pharmaceuticals S.p.A - Dormant Projects 40
Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
BXL-746 41
mesalamine ER 41
Cosmo Pharmaceuticals S.p.A - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Cosmo Pharmaceuticals S.p.A, Key Information 5
Cosmo Pharmaceuticals S.p.A, Key Facts 5
Cosmo Pharmaceuticals S.p.A - Pipeline by Indication, 2014 7
Cosmo Pharmaceuticals S.p.A - Pipeline by Stage of Development, 2014 8
Cosmo Pharmaceuticals S.p.A - Monotherapy Products in Pipeline, 2014 9
Cosmo Pharmaceuticals S.p.A - Partnered Products in Pipeline, 2014 10
Cosmo Pharmaceuticals S.p.A - Partnered Products/ Combination Treatment Modalities, 2014 11
Cosmo Pharmaceuticals S.p.A - Out-Licensed Products in Pipeline, 2014 12
Cosmo Pharmaceuticals S.p.A - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Cosmo Pharmaceuticals S.p.A - Phase III, 2014 14
Cosmo Pharmaceuticals S.p.A - Phase II, 2014 15
Cosmo Pharmaceuticals S.p.A - Phase I, 2014 16
Cosmo Pharmaceuticals S.p.A - Pipeline by Target, 2014 29
Cosmo Pharmaceuticals S.p.A - Pipeline by Route of Administration, 2014 30
Cosmo Pharmaceuticals S.p.A - Pipeline by Molecule Type, 2014 31
Cosmo Pharmaceuticals S.p.A - Pipeline Products by Mechanism of Action, 2014 33
Cosmo Pharmaceuticals S.p.A - Recent Pipeline Updates, 2014 34
Cosmo Pharmaceuticals S.p.A - Dormant Developmental Projects,2014 40
Cosmo Pharmaceuticals S.p.A - Discontinued Pipeline Products, 2014 41
Cosmo Pharmaceuticals S.p.A, Subsidiaries 42